
Opinion|Videos|January 31, 2025
Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases
Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
2
Thyroid eye disease specialists react to the FDA approval of veligrotug-vvze
3
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
4
Pterygium width may help predict corneal optical disturbance
5























